Five PubMed papers to open first: September 1, 2026

This issue covers papers first published or indexed in PubMed from August 25, 2026, at 09:00 through September 1, 2026, at 09:00 (UTC-05:00). The five papers below are ranked by the channel's stated combination of recent citation momentum and journal impact tier. All five records currently show 0 cited-by works, an expected and unstable signal for papers published within days of this issue. Journal tier, randomized or observational design, sample size, endpoint strength, and clinical or research utility break the early ties. 1 2 3 4 5

At a glance

Rank	Paper	Journal and tier	Design and sample	Primary result
1	Immediate ambulatory ECG monitoring in syncope	New England Journal of Medicine; very high impact tier	Open-label RCT; 2,234 randomized	Syncope episodes at 1 year: 1.37 vs 1.58; IRR 0.89, 95% CI 0.68-1.18, P=.42
2	Timing of PCI around TAVI	New England Journal of Medicine; very high impact tier	Open-label noninferiority RCT; 986 randomized	Primary event: 22.2% vs 24.2%; risk difference -2.0 percentage points, 95% CI -7.4 to 3.4, P<.001 for noninferiority
3	PVI-SHAM-AF	The Lancet; very high impact tier	Double-blind sham-controlled RCT; 262 randomized	AFEQT change difference 2.6; 95% CI -2.7 to 8.0, P=.36
4	CMR GUIDE	JAMA; very high impact tier	Open-label RCT; 353 randomized	SCD or HSVA: 7.8% vs 9.2%; HR 0.76, 95% CI 0.37-1.58
5	THESUS-HF II	The Lancet; very high impact tier	Prospective observational cohort; 1,578 included	30-day mortality 11.1%; 180-day mortality 20.6%

1. Immediate Ambulatory Electrocardiographic Monitoring in Syncope

Journal and impact tier: The New England Journal of Medicine, very high impact tier. The PubMed record is dated August 31, 2026, and lists PMID 42670977. 1

Author and affiliation: First author Matthew J Reed is affiliated with the Usher Institute, School of Population Health Sciences, Acute Care Edinburgh, University of Edinburgh, and the Department of Emergency Medicine, Emergency Medicine Research Group Edinburgh, Royal Infirmary of Edinburgh. 1

Design, setting, and sample: This open-label randomized controlled trial ran at 45 hospitals in the United Kingdom. Adults with syncope that remained unexplained after emergency-department evaluation were assigned to 14-day ambulatory ECG monitoring or site-standard care. The trial randomized 2,234 participants: 1,123 to monitoring and 1,111 to standard care. The primary analysis included 1,970 participants. 1

Primary endpoint and quantitative result: The primary endpoint was the mean number of patient-reported syncope episodes at 1 year. The monitoring group reported 1.37 +/- 5.10 episodes versus 1.58 +/- 8.56 with standard care; incidence-rate ratio 0.89, 95% CI 0.68-1.18, P=.42. The trial reported 49 adverse events with monitoring and 8 with standard care; each group had one serious adverse event. 1

Why it matters: A 14-day monitor may improve rhythm detection for selected patients, but this trial's patient-centered primary outcome did not show fewer recurrent syncope episodes at 1 year. The result gives emergency and syncope services a direct test of whether routine early monitoring changes the outcome patients feel.

Limitation and evidence boundary: The trial was open-label, and the primary analysis excluded participants who completed no follow-up. The result applies to adults whose syncope remained unexplained after emergency-department assessment and to the monitoring strategy tested. It does not establish that monitoring has no diagnostic value for particular arrhythmia-risk groups.

Funding or disclosure: The PubMed record lists the British Heart Foundation and National Health Service Research Scotland as funders. 1

Original paper: Immediate Ambulatory Electrocardiographic Monitoring in Syncope

2. Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation

Journal and impact tier: The New England Journal of Medicine, very high impact tier. The PubMed record is dated August 30, 2026, and lists PMID 42670987. 2

Author and affiliation: First author Barbara E Stähli is affiliated with the Department of Cardiology, University Heart Center, University Hospital Zurich, the Center for Translational and Experimental Cardiology, and the University of Zurich, Zurich, Switzerland. 2

Design, setting, and sample: This international, open-label randomized noninferiority trial enrolled patients with severe aortic stenosis and coronary artery disease at 48 European centers. The trial randomized 986 participants: 498 to TAVI first and 488 to PCI first. The composite primary endpoint included death, nonfatal myocardial infarction, ischemia-driven revascularization, relevant rehospitalization, and major or life-threatening bleeding at 1 year. 2

Primary endpoint and quantitative result: A primary-endpoint event occurred in 105 patients (22.2%) with TAVI first versus 112 (24.2%) with PCI first; risk difference -2.0 percentage points, 95% CI -7.4 to 3.4, P<.001 for noninferiority. Serious adverse events occurred in 264 and 273 patients, respectively. 2

Why it matters: The trial directly addresses a common sequencing decision in patients who need both valve replacement and coronary intervention. Within the prespecified noninferiority margin, the TAVI-first strategy produced a similar 1-year composite outcome to PCI first. The result gives heart teams evidence to consider the valve procedure first when the patient's anatomy and clinical priorities support that sequence.

Limitation and evidence boundary: The trial was open-label, and the composite endpoint combines events with different clinical meanings. Noninferiority applies to the tested population, strategies, follow-up period, and 6.6-percentage-point margin. The result does not identify one sequence as superior for every coronary anatomy or urgent ischemic presentation.

Funding or disclosure: The PubMed record lists University Hospital Zurich and others as funders; the grant agency field names Edwards Lifesciences. 2

Original paper: Timing of PCI in Patients Undergoing Transcatheter Aortic-Valve Implantation

3. Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF)

Journal and impact tier: The Lancet, very high impact tier. The PubMed record is dated August 30, 2026, and lists PMID 42669307. 3

Author and affiliation: First author Rolf Wachter is affiliated with the Department of Cardiology, University Hospital Leipzig, Leipzig, Germany. 3

Design, setting, and sample: PVI-SHAM-AF was a double-blind, sham-controlled, randomized multicentre trial at nine sites in Germany and Poland. Adults with symptomatic paroxysmal or persistent atrial fibrillation were assigned in a 2:1 ratio to catheter ablation or a sham procedure. The trial randomized 262 patients: 173 to ablation and 89 to sham. The primary endpoint was the between-group difference in change from baseline to 6 months in the Atrial Fibrillation Effect on the Quality-of-life Questionnaire (AFEQT) summary score. 3

Primary endpoint and quantitative result: Mean AFEQT scores increased from 61.3 to 81.1 with ablation and from 59.2 to 74.9 with sham. The between-group change was 2.6 points by the Hodges-Lehmann estimate, 95% CI -2.7 to 8.0, P=.36. One death occurred in each group. Procedure-related or possibly related serious adverse events occurred in 6 ablation patients and 4 sham patients; one ischemic stroke occurred in the sham group. 3

Why it matters: Both groups reported improved AF-related quality of life, while the sham-controlled comparison did not demonstrate superiority for ablation at 6 months. The design separates the procedure's effect from expectation, contact with care, and other trial effects more directly than an unblinded comparison.

Limitation and evidence boundary: The sample was modest, the allocation ratio was 2:1, and 12-month follow-up remains ongoing. The six-month result addresses AF-related quality of life, rather than every symptom, rhythm, hospitalization, or long-term outcome. Serious adverse-event counts also require context from the full trial report and longer follow-up.

Funding or disclosure: The PubMed record lists Helios Gesundheit, Förderung Leipziger Herzmedizin, as the funder. 3

Original paper: Catheter ablation for symptomatic atrial fibrillation (PVI-SHAM-AF)

4. Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%: The CMR GUIDE Randomized Clinical Trial

Journal and impact tier: JAMA, very high impact tier. The PubMed record is dated August 28, 2026, and lists PMID 42663169. 4

Author and affiliation: First author Joseph B Selvanayagam is affiliated with Flinders University, Adelaide, South Australia, Australia. 4

Design, setting, and sample: This open-label randomized clinical trial enrolled adults with ischemic or nonischemic cardiomyopathy, LVEF 36%-50%, CMR-defined myocardial scar, and guideline-directed medical therapy at 18 sites in Australia, Germany, and the United Kingdom. The trial randomized 353 participants to a primary-prevention ICD (180) or an implantable loop recorder (173). Median follow-up was 6.3 years. 4

Primary endpoint and quantitative result: The composite of sudden cardiac death or hemodynamically significant ventricular arrhythmia occurred in 7.8% with an ICD versus 9.2% with an implantable loop recorder; HR 0.76, 95% CI 0.37-1.58. Sudden cardiac death occurred in 1.7% versus 5.8% (HR 0.26, 95% CI 0.07-0.95), while hemodynamically significant ventricular arrhythmia occurred in 6.7% versus 3.5% (HR 1.77, 95% CI 0.65-4.81). In the prespecified age analysis, the composite occurred in 3.3% versus 10.0% among participants younger than 70 years (HR 0.28, 95% CI 0.09-0.89) and in 16.9% versus 7.5% among those aged 70 years or older (HR 2.33, 95% CI 0.75-7.26); the interaction P value was .01. 4

Why it matters: The overall composite estimate crosses substantial benefit and harm, so the trial did not show a reduction in the primary composite outcome for the full scar-positive, LVEF 36%-50% population. The divergent component estimates and age interaction identify a clinically important subgroup question for further study.

Limitation and evidence boundary: The trial was open-label and enrolled 353 participants, with 70% having LVEF of at least 40% and 72% an ischemic etiology. The age interaction comes from a prespecified subgroup analysis and should be interpreted with the wide confidence intervals and the overall neutral composite in view. The result does not support applying the younger or older subgroup estimate as a universal ICD rule.

Funding or disclosure: The indexed record has no separate grant field. Its conflict statement mentions grants from the National Heart Foundation of Australia and the Australian National Health and Medical Research Council, along with other listed relationships. 4

Original paper: Cardiovascular Magnetic Resonance to Guide Defibrillator Implantation for LVEF of 36% to 50%

5. Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II)

Journal and impact tier: The Lancet, very high impact tier. The PubMed record is dated August 30, 2026, and lists PMID 42669305. 5

Author and affiliation: First author Karen Sliwa is affiliated with the Cape Heart Institute, Department of Medicine and Cardiology, Faculty of Health Sciences, University of Cape Town, Cape Town, South Africa. 5

Design, setting, and sample: THESUS-HF II was a prospective, multicentre observational cohort study at 50 hospitals in 17 African countries. Adults with acute heart failure were enrolled during seven 24-hour surveillance periods within an 8-week site-specific window. Of 1,741 patients assessed, 1,578 entered the cohort. De novo acute heart failure accounted for 1,007 of 1,568 presentations (64.2%). 5

Primary endpoint and quantitative result: The leading recorded etiologies were hypertensive heart disease in 36.5%, cardiomyopathy in 23.4%, and ischemic heart disease in 23.3%. In-hospital mortality was 8.7% (134/1,542); 30-day mortality was 11.1% (160 deaths); and 180-day mortality was 20.6% (255 deaths). Among patients with discharge data, renin-angiotensin-aldosterone system inhibitors were prescribed to 73.9%, beta blockers to 76.9%, mineralocorticoid receptor antagonists to 71.9%, and SGLT2 inhibitors to 54.7%; fewer than half reached target doses. 5

Why it matters: The cohort describes acute-heart-failure presentation, treatment patterns, and outcomes across a large network spanning 17 African countries. The combination of a relatively young cohort, high short- and medium-term mortality, and incomplete delivery of target-dose therapy gives health systems and researchers concrete variables to investigate.

Limitation and evidence boundary: The observational design supports description and association, rather than causal claims about treatment or etiology. Ascertainment and diagnostic capability may have contributed to the apparent etiologic shift from the earlier THESUS-HF study. Of 1,567 patients in time-to-event analyses, 528 (33.7%) were lost before 180-day follow-up, which limits interpretation of long-term mortality.

Funding or disclosure: Funders were the Cape Heart Institute and University of Cape Town, Hippocrate Foundation, The Heart Initiative, and Pan African Society of Cardiology. 5

Original paper: Aetiology, management, and outcomes of acute heart failure in 17 African countries (THESUS-HF II)

What to open first

Syncope and emergency care: Open the ASPIRED trial first if your question is whether immediate 14-day ECG monitoring changes patient-reported recurrence after an unexplained syncope evaluation.
Structural and interventional cardiology: Open the TAVI-PCI trial first if your question is procedural sequencing in severe aortic stenosis with coronary artery disease.
Atrial fibrillation: Open PVI-SHAM-AF first if your question is how much symptom and quality-of-life improvement remains after a sham-controlled comparison.
Ventricular arrhythmia prevention: Open CMR GUIDE first if your question is whether scar-defined risk can extend ICD decisions above the conventional LVEF threshold.
Heart-failure systems and global cardiology: Open THESUS-HF II first if your question is the current burden, treatment pattern, and follow-up loss across African acute-heart-failure care.

These reading paths identify which original paper answers each question. They leave treatment and implementation decisions to the clinical context and the reader's judgment.